Dagbay KB, Treece E, Streich Jr. FS, Jackson JW, Faucette RR, Nikiforov A, Lin SC, Boston CJ, Nicholls SB, Capili AD, Carven GJ. Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015. 2020. Journal of Biological Chemistry. DOI: 10.1074/jbc.RA119.012293

Martin CJ, Abhishek D, Littlefield C, Ashish K, Chapron C, Wawersik S, Dagbay, KB, Brueckner, CT, Nikiforov A, Danehy Jr FT, Streich Jr. FS, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T. Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. 2020. Science Translational Medicine. 12, eaay8456.

Cote CM, Jackson J, Pirruccello-Straub M, Carven GJ, Wawersik S. A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation. 2019. SLAS Discovery.

Long, K., O’Shea, K., Khairallah, R., et al. Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy. 2018. Human Molecular Genetics, ddy382

Pirruccello-Straub M, Jackson J, Wawersik S, Webster MT, Salta L, Long K, McConaughy W, Capili A, Boston C, Carven GJ, Mahanthappa NK, Turner KJ, Donovan A. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. 2018. Sci Rep 8:20524-9

Le VQ, Iacob RE, Tian Y, McConaughy W, Jackson J, Su Y, Zhao B, Engen JR, Pirruccello-Straub M, Springer TA. Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation. 2017. EMBO J 37(3): 384-97

World Muscle Society Congress – October 2019

American Association for Cancer Research (AACR) Annual Meeting – April 2019
Defeating primary checkpoint resistance: SRK-181 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting — November 2018
Defeating checkpoint resistance: Highly specific inhibition of latent TGFβ1 activation renders resistant solid tumors vulnerable to PD-1 blockade

12th International BMP Conference — October 2018
RGMc-selective antibodies modulate iron homeostasis in vivo

Gordon Research Conference — March 2018
Discovery of an isoform-specific inhibitor of TGFb1 activation using antibody display technology

European SMA Research Congress — January 2018
Inhibition of myostatin activation by SRK-015 promotes muscle strength in a multiple mouse models of SMA

ASN Kidney Week — November 2017
A novel, highly specific TGFβ1 inhibiting antibody demonstrates antifibrotic activity without cardiotoxicity

CURE SMA Annual Conference — June 2017
Scholar Rock’s Novel Approach to Improving Muscle Function in SMA Patients

Federation of American Societies for Experimental Biology — April 2017
Highly specific inhibition of TGFβ1 activation with antibody SR-AB1 has antifibrotic activity

Gordon Research Conference— August 2017
Identification of LTBP Complex-Specific Inhibitors of Latent TGFβ1 Activation

“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2020 Scholar Rock All Rights Reserved.
Back to Top

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel